Raltitrexed (Tomudex):: an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity

被引：62

作者：

Köhne, CH

Thuss-Patience, P

Friedrich, M

Daniel, PT

Kretzschmar, A

Benter, T

Bauer, B

Dietz, R

Dörken, B

机构：

[1] Humboldt Univ, Med Fak Charite, Virchow Klinikum,Robert Rossle Klin, Dept Haematol Oncol & Tumor Immunol, D-13125 Berlin, Germany

[2] Humboldt Univ, Med Fak Charite, Virchow Klinikum,Franz Volhard Klin, Dept Clin & Mol Cardiol, D-13125 Berlin, Germany

来源：

BRITISH JOURNAL OF CANCER | 1998年 / 77卷 / 06期

关键词：

5-fluorouracil; cardiotoxicity; raltitrexed; colorectal neoplasms;

D O I：

10.1038/bjc.1998.160

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Two patients with proven 5-fluorouracil (5-FU)-associated cardiotoxicity were treated with the specific thymidylate synthase inhibitor raltitrexed safely, without evidence of cardiotoxicity. Raltitrexed might be an alternative for patients with advanced colorectal cancer and 5-FU-associated cardiotoxicity. 5-FU cardiotoxicity is not due to the antineoplastic mechanisms via thymidilate synthase.

引用

页码：973 / 977

页数：5

共 22 条

[1]

AKHTAR SS, 1993, ONCOLOGY, V50, P441

[2] FLUOROURACIL CARDIOTOXICITY [J].

ANAND, AJ .

ANNALS OF PHARMACOTHERAPY, 1994, 28 (03) :374-378

[3] 5-FLUOROURACIL-INDUCED CORONARY VASOSPASM [J].

BURGER, AJ ;

MANNINO, S .

AMERICAN HEART JOURNAL, 1987, 114 (02) :433-436

[4]

COLLINS C, 1987, CANCER TREAT REP, V71, P733

[5] 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia [J].

Cunningham, D ;

Zalcberg, JR ;

Rath, U ;

Olver, I ;

VanCutsem, E ;

Svensson, C ;

Seitz, JF ;

Harper, P ;

Kerr, D ;

PerezManga, G ;

Azab, M ;

Seymour, L ;

Lowery, K ;

Ackland, SP ;

Basser, RL ;

Clarke, SJ ;

Goldstein, D ;

Green, MD ;

Grygiel, JJ ;

McKendrick, JJ ;

Millward, MJ ;

Olver, IN ;

Tattersall, MHN ;

Thomson, DB ;

Jakesz, R ;

Buset, M ;

Tueni, EA ;

VanCutsem, EJD ;

Bauer, J ;

Beska, F ;

Adenis, A ;

Brunet, R ;

Francois, E ;

Paillot, B ;

Rougier, P ;

Fink, UFW ;

Knuth, KRA ;

Koenig, HJ ;

Bohme, MWJ ;

Wander, HE ;

Amadori, D ;

Frassineti, L ;

Cocconi, G ;

Passalacqua, R ;

Frigerio, F ;

Barni, S ;

Luporini, G ;

Labianca, R ;

Marini, G ;

Zaniboni, A .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) :1945-1954

[6]

DENT RG, 1975, LANCET, V1, P347

[7]

GAMELIN E, 1991, B CANCER, V78, P1147

[8] EXPECTANCY OR PRIMARY CHEMOTHERAPY IN PATIENTS WITH ADVANCED ASYMPTOMATIC COLORECTAL-CANCER - A RANDOMIZED TRIAL [J].

GLIMELIUS, B ;

PAHLMAN, L ;

GRAF, W ;

ADAMI, HO ;

TVEIT, K ;

HANSEN, J ;

LILJEGREN, G ;

DOMELoF, L ;

LJUNGQVIST, U ;

BERGMAN, L ;

ENANDER, LK ;

UNDERSKOG, I ;

SoDERBERG, M ;

JoNSSON, PE ;

HAFSTRoM, L ;

HEUMAN, R ;

ATHLIN, L ;

SASSNER, P ;

SELLSTRoM, H .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :904-911

[9]

Harper P, 1997, P AN M AM SOC CLIN, V16, p228a

[10] CARDIAC TOXICITY OF 5-FLUOROURACIL - A STUDY ON 1083 PATIENTS [J].

LABIANCA, R ;

BERETTA, G ;

CLERICI, M ;

FRASCHINI, P ;

LUPORINI, G .

TUMORI, 1982, 68 (06) :505-510

← 1 2 3 →